GSK says staying on sidelines in Astra, Pfizer fight

GlaxoSmithKline (GSK.L) is just an "interested observer" as U.S. drugmaker Pfizer (PFE) battles to win British rival AstraZeneca (AZN.L) in a potential $100 billion deal, GSK's chief executive said on Wednesday. Andrew Witty said he hoped Pfizer would take a "rational" decision to keep drug research in Britain if the deal went through, but he played down the idea that GSK might intervene as a "white knight" counterbidder.

via Business News - Yahoo Finance http://ift.tt/1md8jGv